October 24, 2026
Celebrating Caregivers – "The People Who Keep Showing Up for You"
Read Ester's story and insights on caregiving while living with hereditary ATTR amyloidosis, including lessons on resilience, support, and self-care.
Read More ›
October 15, 2026
The Signs Were There: How Pete Shaw and His Team Faced an Unexpected Opponent
For former professional football player Pete Shaw, recognizing the signs of hATTR-CM meant looking beyond the expected. Read his story and path to answers.
Read More ›
August 26, 2026
Advancing Earlier Diagnosis and Coordinated Care in ATTR-CM
For patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the path to effective care often begins with a challenge: receiving the right diagnosis before the disease irreversibly advances.
Read More ›
March 27, 2026
Five Things to Know about TRITON-CM & How Community Insight is Shaping the Future of ATTR- ...
TRITON-CM, Alnylam's Phase 3 clinical trial evaluating nucresiran, a third-generation investigational RNAi therapeutic for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), represents one of the largest global studies ever conducted in this disease.
Read More ›
September 6, 2023
First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR Am ...
The Amyloidosis Alliance has published the first-ever consensus recommendations for patient- and family-centred holistic care in ATTRv.
Read More ›
September 6, 2021
Co-Creating with Patients, for Patients: Addressing Unmet Needs in Conversations about AT ...
Collaborating with patient organizations and patients is an essential part of our efforts to support people living with a complex rare disease like...
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site